The caveat to this is that the secretion of GDF15 during cancer, as it appears so for inflammatory infections, is presumably an adaptive response, so blocking GDF15/GFRAL signalling may worsen the disease and other symptoms. This evidence concerns the gene GDF15 and cancer.